Advertisement

Malaria Journal

, 13:P90 | Cite as

Modelling the effects of combining pre-erythrocytic vaccines against Plasmodium falciparum

  • Andrew Walker
  • Sunetra Gupta
Open Access
Poster presentation
  • 526 Downloads

Keywords

Malaria Plasmodium Falciparum Malaria Infection Subunit Vaccine Malaria Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Background

A high efficacy multi-stage multi-epitope malaria vaccine would be an invaluable weapon in the eradication of malaria. Currently, the best progress in subunit vaccine research has been seen in targeting pre-erythrocytic (PE) stages of the parasite. In phase IIa trials, RTS,S in adjuvant was capable of inducing sterile protection in 50% of individuals [1], and ME-TRAP in a heterologous prime-boost regime saw around 21% efficacy [2]. Here we present a mathematical model investigating the effects of combining these two approaches.

Materials and methods

A mathematical model was developed to describe Plasmodium falciparum parasite dynamics within an immunonaive host. The model was parameterised using data from non-vaccine recipients in Controlled Human Malaria Infection (CHMI) studies, and then used to study the effects of vaccine induced immune responses against the sporozoite and hepatocytic stages of the life cycle, and the effects of combining them.

Results

Using data from phase IIa trials of RTS,S [1]and ME-TRAP [2], we predict that near total sterile protection can be achieved by combining these vaccines. Even very low efficacy (<1%) vaccines are shown to combine to confer sterile protection in up to 43% of individuals.

Conclusions

We find a heterologous vaccine treatment to act synergistically: the efficacy of the combination far outweighs the sum of its parts. This suggests that a high efficacy multi-stage vaccine may well be within reach, and may utilise some of the tools presently available.

References

  1. 1.
    Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois M, Lievens M, Cohen J, Ballou WR, Heppner DG: Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection. J Infect Dis. 2009, 200: 337-346. 10.1086/600120.CrossRefPubMedGoogle Scholar
  2. 2.
    Ewer KJ, O’Hara GA, Duncan CJA, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AVS: Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013, 4: 2836-PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Walker and Gupta; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Andrew Walker
    • 1
  • Sunetra Gupta
    • 1
  1. 1.Department of ZoologyUniversity of OxfordOxfordUK

Personalised recommendations